GCTA The Gastroesophageal Cancer Therapeutics Accelerator (GCTA) at MSK is focused on uncovering and overcoming mechanisms of therapeutic resistance in gastroesophageal cancer (GEC). We integrate biomarker-driven approaches into all MSK-led clinical trials and leverage advanced technologies—including digital pathology, spatial transcriptomics, proteomics, immunopeptidomics, genomics, and AI-enabled analysis of large datasets—to identify new therapeutic targets.